Trial Profile

A phase 1b/2a clinical trial of CLR-121125 in Triple-negative-breast-cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Jun 2025 According to Cellectar Biosciences media release, Cellectar Biosciences and Nusano formed an supply agreement to support clinical trials of CLR 125 for triple negative breast cancer and CLR 225 for pancreatic cancer.
13 Mar 2025 According to Cellectar Biosciences media release, the company received clearance for an IND and is prepared to initiate a Phase 1b/2a dose-finding study with CLR 121125 in triple-negative breast cancer.
17 Dec 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com